Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study
| Autor: | Shishir K. Maithel, Eric J. Silberfein, Cary Hsu, Maria C. Russell, Emily L. Ryon, Annie Wang, Rachel M. Lee, Sommer Luu, Michael K. Turgeon, Neha Goel, Adam C. Yopp, Adriana C. Gamboa, Ann Y. Lee |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular Referral medicine.medical_treatment Improved survival Article Resection 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Long term outcomes Humans Stage (cooking) Retrospective Studies Chemotherapy Hepatology business.industry Liver Neoplasms Gastroenterology virus diseases Hepatitis C medicine.disease United States digestive system diseases Liver Transplantation 030220 oncology & carcinogenesis Hepatocellular carcinoma 030211 gastroenterology & hepatology business |
| Zdroj: | HPB (Oxford) |
| ISSN: | 1365-182X |
| Popis: | BACKGROUND: Widespread HCV treatment for hepatocellular carcinoma (HCC) patients remains limited. Our aim was to evaluate the association of HCV treatment with survival and assess barriers to treatment. METHODS: Patients in the U.S. Safety Net Collaborative with HCV and HCC were included. Primary outcome was overall survival (OS). Secondary outcomes were recurrence-free survival (RFS) and barriers to receiving HCV treatment. RESULTS: Of 941 patients, 57% received care at tertiary referral centers (n=533), 74% did not receive HCV treatment (n=696), 6% underwent resection (n=54), 17% liver transplant (n=163), 50% liver-directed therapy (n=473), and 7% chemotherapy (n=60). HCV treatment was associated with improved OS compared to no HCV treatment (70 vs 21 months, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|